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Oral   anticoagulation   (OAC)   is   commonly   used   to   prevent   or   treat   thromboembolic  
events   in   patients   with   conditions   such   as   atrial   fibrillation   (AF)   and   venous  
thromboembolism   (VTE).   Until   2010,   vitamin   K   antagonists   (VKA)   were   the   only  
available   type  of  OAC.  While  VKAs  are  effective  when  used  correctly,  with   time   in  
therapeutic  range  (TTR)  of  70%  or  greater,  they  have  drawbacks.  The  need  for  regular  
monitoring,  concerns  about  remaining  within  a  pre-­set  International  Normalised  Ratio  
(INR)   range   and   achieving   high   proportion   of   TTR,   drug-­,   food-­   and   alcohol-­
interactions,  and  the  possibility  of  recurrent  dose  adjustments,  may  negatively  affect  
patients’  quality  of  life  (QoL)  and  satisfaction  with  treatment.  This,  in  turn,  can  have  an  
influence  on  patients’  adherence  and  persistence  rates.  From  a  clinical  perspective,  
reduced   treatment   adherence   and   persistence   can   also   influence   physicians’  
willingness  to  prescribe  OACs.    
The  NOACs  have  overcome  some  of  the  inherent  limitations  associated  with  VKAs,  
having  fewer  drug  and  food  interactions,  a  consistent  dosing  regimen,  and  a  stable  
pharmacokinetic   profile,   hence   requiring   less   frequent   monitoring   (periodic   renal  
function   testing   only).   It   is   worth   acknowledging   that   some   patients   may   feel   that  
regular   INR   monitoring   and   the   associated   contact   with   health   professionals   is  
preferable,  as  this  may  offer  an  added  sense  of  security.  However,  NOACs  appear  to  
present  a  welcome  solution   to   some  of   the  practical   issues  associated  with  VKAs,  
which   have   been   shown   to   affect   treatment   satisfaction   [1,   2].   Unsurprisingly,   the  
NOACs  have  been   increasingly   used   in   clinical   practice,   generally   offering   relative  
effectiveness,  safety  and  convenience  compared   to   the  VKAs  and   leading   to  many  
prescribers  switching  from  VKA  to  NOACs  in  real  world  practice  [3-­6].      
The   study   by   Katerenchuk   et   al   in   this   issue   of  Thrombosis   and   Haemostasis   [7]  
suggests  that  patients  prefer  NOACs  over  VKAs.  Their  systematic  review  and  meta-­
analysis   included   four   randomised   controlled   trials   (RCT)   and   16   observational  
studies,   with   a   total   of   18,684   patients   receiving   OAC   for   either   AF   or   VTE   and  
demonstrated  that  compared  to  patients  treated  with  VKAs,  those  treated  with  NOACs  
reported  less  burden  and  greater  treatment  benefits.  Participants  who  switched  from  
NOAC   to   VKA   also   reported   a   reduction   in   treatment   burden   and   patients’   global  
satisfaction  was  improved  by  treatment  with  NOACs  relative  to  VKAs  [7].  Participants  
reported   that   NOAC   treatment  was   less   burdensome,  more   convenient,   and  more  
effective   than   VKA   treatment.   Overall,   the   systematic   review   by   Katerenchuk   and  
colleagues  suggests  that  patients  are  more  satisfied  with  NOAC  treatment  relative  to  
VKAs,  largely  due  to  reduced  treatment  burden.    
The   systematic   review   and   meta-­analysis   was   robustly-­conducted,   with   study  
selection  and  data  extraction  carried  out   independently  by  two  researchers.  Risk  of  
bias  was   independently   assessed   and   observational   studies  with   high   risk   of   bias  
scores   were   excluded   from   the   meta-­analysis.   However,   there   was   considerable  
heterogeneity   between   the   included   studies   and   outcomes   relied   on   self-­reported  
patient  data,  which  introduces  potential  bias  into  the  results.  None  of  the  sub-­group  
analyses  were   statistically   significant   [7]   and   there  was   no   significant   difference   in  
patients’   overall   perception   of   NOAC   versus   VKA   when   assessed   using   different  
satisfaction  scales.  
An  important  element  of  long-­term  anticoagulation  treatment  is  increased  adherence  
and  persistence  with  OAC  [8].  It  is  hoped  that  greater  patient  satisfaction  with  OACs  
can   help   achieve   this,   as   patients   who   are   satisfied   with   the   clinical   effects   and  
practical   aspects   of   their  medication   should   ideally   be  more  willing   to   adhere   and  
persist  with  that  medication.  Higher  treatment  satisfaction  scores  were  associated  with  
better  adherence  to  OAC  amongst  Australian  patients  with  AF  [9].  Reducing  treatment  
burden  can  also  promote  better  adherence  and  persistence.  AF  patients  appear   to  
rate   their   treatment   burden   as   high,   with   1   in   5   AF   patients   questioning   the  
sustainability  of  their  treatment  as  a  result  [10].  Risk  of  non-­adherence  among  patients  
with  AF  was  significantly  lower  among  participants  taking  a  NOAC  compared  to  those  
taking  a  VKA  (p<0.001)  [11].  A  recent  Korean  study  exploring  adherence  to  NOACs  in  
a   single   cardiology   department   reported   92%   adherence   (measured   as   ≥80%  
prescribed  doses  taken)  [12].    
It  is  important  to  remember  that  the  same  treatment  regimen  may  be  rated  as  having  
different   treatment  burden  by  different  patients.  A  patient’s  diagnosis,  demographic  
factors,   and   comorbidities   all   affect   how   that   patient   interprets   OAC-­associated  
treatment   burden   (Figure   1).   In   Katerenchuk’s   systematic   review,   there   were  
considerable  differences  between  the  AF  and  VTE  patient  groups  [7].  Patients  with  
VTE  were  an  average  of  15  years  younger  than  patients  with  AF,  and  there  were  more  
men   in   the   AF   group.   Furthermore,   not   all   VTE   patients   required   lifelong   OAC  
treatment,  which   is   an   important   distinction  given   that   patients’   adherence   to  OAC  
tends   to   reduce   over   time   [13].   A   personalised   approached,   whereby   clinicians  
regularly   assess   the   impact   of   a   specific   treatment   on   the   individual   patient,   is  
therefore  needed  [14]  and  various  tools  are  available  to  assist  physicians  with  their  
assessment  of  patients’  disease  burden  and  treatment  satisfaction  levels  [15].  
Insert  Figure  1  
However,  the  relationship  between  treatment  satisfaction  levels  and  adherence  rates  
is   complex.  A  French   study   [16]   that   assessed  AF  patients’   treatment   satisfaction,  
adherence  to  treatment,  and  QoL  scores  reported  mixed  findings:  patients’  satisfaction  
with  NOACs  was  significantly   higher   than   their   satisfaction  with  VKAs   (p  <  0.001).  
However,   greater   patient   satisfaction   with   NOACs   did   not   translate   to   better  
medication   adherence   or   increased  QoL   scores   (p=0.72   and   p=0.29   respectively).  
Among  patients  with  VTE,  it  has  been  reported  that  adherence  was  not  influenced  by  
either   OAC-­associated   QoL   scores   or   practical   concerns   [17].   It   appears   that   the  
perceived  ease  of  taking  NOACs  versus  VKAs  does  not  necessarily  always  translate  
to  better  adherence  rates.      
What  does  this  mean  for  clinical  practice?  Given  that  many  patients,  particularly  those  
with  AF,  require  long-­term  OAC,  physicians  and  other  healthcare  professionals  need  
to  optimise  the  likelihood  of  patient  satisfaction  with,  and  understanding  of,  treatment  
to  increase  medication  adherence  and  persistence.  Any  treatment  plan  needs  to  be  
realistic,  both  in  terms  of  its  treatment  outcomes,  which  should  be  discussed  with  the  
patient   and   incorporate   patient’s   views   and   treatment   goals   and   be   mindful   of   its  
practical   demands   of   the   treatment   regimen   on   patients.   Ideally,   any   treatment  
regimen  would  try  to  minimise  the  negative  impact  on  a  patient’s  QoL  [14].  Improving  
patients’  understanding  of  their  disease  and  the  benefits/risk  of  treatment  can  help  to  
minimise/off-­set   treatment   burden   because   appreciation   of   the   necessity   of   the  
treatment  can   result   in  acceptance  of   the  associated   treatment  burden  and   reduce  
dissatisfaction.  As  highlighted  in  the  new  European  Society  of  Cardiology  Guidelines  
on   the  management   of   AF   [18],   the   key   to   improving   patient   outcomes,   including  
patient  satisfaction  with  treatment,  is  a  patient-­centred  approach  to  the  management  
of  chronic  disease.    
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Figure  1:  Factors  contributing  to  effective  management  of  AF  
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